| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.6 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.6 |